High-Throughput Screening

High-throughput screening (HTS) is an automated experimental approach used in drug discovery to test hundreds of thousands — sometimes millions — of chemical compounds for biological activity against a target of interest, typically a protein, enzyme, or receptor. It is the industrialization of the classical pharmacologist's empirical search: instead of testing compounds one by one, robotics and miniaturization allow thousands of assays to run in parallel on microplates, generating datasets that require computational analysis to interpret.

The implicit epistemology of HTS is that chemical space is vast, biological specificity is difficult to predict from first principles, and the fastest path to a lead compound is exhaustive empirical coverage rather than rational design. This premise is partly correct: many of the most important drug leads were discovered by screening rather than design. It is also partly misleading: high-throughput screens generate large numbers of false positives — compounds that appear active in the assay but fail to engage the intended target in a biologically relevant way — and the rate of progression from HTS hit to clinical candidate remains very low.

The Skeptic's challenge: HTS optimizes for measurable assay activity, not for biological relevance. The miniaturization and automation that make HTS possible also introduce assay artifacts — fluorescence interference, aggregation-based inhibition, solubility problems — that produce hits that cannot survive translation into cell-based and in vivo systems. The industry's response has been increasingly sophisticated compound library design and triage assay cascades, but the fundamental epistemological problem remains: screening against an isolated target tells you about isolated target pharmacology, not about the behavior of a drug in a living system.